Lisinopril vs Amlodipine: Long-Term Durability of Blood Pressure Response

What the Trials Actually Show About Long-Term Durability

Durability of antihypertensive response means a drug keeps blood pressure controlled month after month and year after year, not just in the first weeks of treatment. Both lisinopril and amlodipine maintain statistically significant blood pressure reductions beyond five years in randomized data, but amlodipine's pharmacokinetic profile gives it a measurable edge in trough blood pressure control over a 24-hour dosing interval.

ALLHAT: The Definitive Long-Term Comparison

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357, mean follow-up 4.9 years) is the largest head-to-head antihypertensive trial ever conducted. Published in JAMA 2002, it compared chlorthalidone, amlodipine, and lisinopril in high-risk hypertensive adults aged 55 or older [1].

For the primary outcome (fatal coronary heart disease or nonfatal MI), amlodipine and lisinopril were statistically equivalent to chlorthalidone: relative risk for amlodipine vs. Chlorthalidone was 0.98 (95% CI 0.90-1.07), and for lisinopril vs. Chlorthalidone was 0.99 (95% CI 0.91-1.08) [1]. Neither drug separated from the diuretic on the primary endpoint.

Where the drugs diverged was in secondary outcomes tied to blood pressure durability. Lisinopril produced slightly higher systolic blood pressure at years 4-5 compared with amlodipine, and that gap tracked with outcomes. Lisinopril was associated with a 15% higher risk of stroke (RR 1.15, 95% CI 1.02-1.30, P<0.02) and a 10% higher risk of combined cardiovascular disease events compared with chlorthalidone [1]. Amlodipine did not carry this stroke penalty.

ASCOT-BPLA: Amlodipine-Based Strategy vs. Beta-Blocker Strategy

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA, N=19,257, median 5.5 years) randomized patients to amlodipine (with perindopril added as needed) versus atenolol (with bendroflumethiazide added as needed). Published in The Lancet in 2005, the trial was stopped early because the amlodipine-based arm was clearly superior [2].

Amlodipine-based therapy reduced fatal and nonfatal stroke by 23% (P<0.0001), total cardiovascular events by 16% (P<0.0001), and all-cause mortality by 11% (P=0.0247) [2]. While ASCOT-BPLA does not pit amlodipine directly against lisinopril, it anchors the case that amlodipine-based combination strategies produce durable cardiovascular protection over multi-year follow-up. Perindopril (another ACE inhibitor closely related to lisinopril in mechanism) was added in the amlodipine arm in 60% of patients by year 5, suggesting the combination strategy outperforms monotherapy regardless of which agent anchors it.

Why Amlodipine Has a Pharmacokinetic Durability Advantage

Amlodipine's plasma half-life is 30-50 hours, giving it the longest half-life of any commonly prescribed antihypertensive [3]. A missed dose produces far less rebound blood pressure elevation than a missed dose of lisinopril, which has a half-life of roughly 12 hours. Lisinopril's trough-to-peak ratio (the ratio of blood pressure reduction at the end of the dosing interval to the peak reduction) sits in the range of 0.60-0.80 once daily. Amlodipine's trough-to-peak ratio approaches 0.80-1.00, meaning blood pressure control is nearly as good at 24 hours post-dose as it is at peak [3].

In real-world patients who occasionally miss a dose, that pharmacokinetic difference translates to fewer brief blood pressure spikes and more consistent 24-hour coverage.

Cardiovascular Outcomes Beyond Blood Pressure Numbers

Blood pressure as a surrogate is useful, but clinicians and patients care about strokes, heart attacks, and heart failure hospitalizations. Long-term durability of response means the drug keeps cardiovascular events low across a five-to-eight-year horizon.

Coronary Events

In ALLHAT, both amlodipine and lisinopril were equivalent to chlorthalidone on fatal CHD and nonfatal MI [1]. Neither drug produced a statistically superior coronary outcome compared to the other. When amlodipine and lisinopril are compared indirectly through ALLHAT's three-arm structure, coronary event rates are nearly identical, which means the choice between them for a patient whose primary concern is MI prevention can reasonably be guided by tolerability and comorbidities.

Stroke Prevention

Stroke reduction is where lisinopril falls short in ALLHAT. The 15% higher stroke risk observed with lisinopril versus chlorthalidone in ALLHAT [1] is attributed primarily to a 2 mmHg systolic blood pressure difference that accumulated over the trial. Amlodipine did not show this disadvantage. For patients with prior stroke or TIA, the blood pressure durability data favor amlodipine over lisinopril as the anchor agent.

Heart Failure

ALLHAT found that amlodipine was associated with a significantly higher rate of combined heart failure events (RR 1.38 vs. Chlorthalidone, P<0.001), though much of this signal was driven by hospitalized heart failure without fatal outcomes [1]. Lisinopril's heart failure rate was also higher than chlorthalidone (RR 1.19), but the gap was smaller. For patients with established reduced ejection fraction heart failure, ACE inhibitors including lisinopril are a guideline-directed therapy with a mortality benefit, while dihydropyridine CCBs like amlodipine are generally considered neutral on survival in HFrEF and should not be used preferentially [4].

Tolerability Across Years of Therapy

A drug's long-term durability depends not only on pharmacology but on whether patients actually take it. Discontinuation from side effects is a primary driver of real-world antihypertensive failure.

ACE Inhibitor Cough: The Most Common Reason Patients Stop Lisinopril

ACE inhibitor-induced dry cough affects an estimated 10-15% of White patients and up to 30-40% of East Asian patients on lisinopril, caused by bradykinin accumulation in the airways [5]. This is not a dose-dependent effect and does not resolve with dose reduction. Patients who develop the cough face a binary choice: switch to an ARB (such as losartan or valsartan) or accept a persistent cough. Because the cough often begins within the first 1-3 months and continues for the life of therapy, it is the single largest practical barrier to lisinopril's long-term durability in real-world populations.

Amlodipine's Peripheral Edema: Common but Not Dangerous

Peripheral edema (ankle swelling) affects up to 10.8% of patients taking amlodipine 10 mg daily versus 1.8% on placebo [6]. The edema is caused by preferential dilation of arteriolar over venous vessels, shifting fluid into the interstitium. It is dose-dependent: patients on 5 mg daily experience edema rates closer to 5%. Unlike edema caused by heart failure, amlodipine-induced pedal edema is benign and does not reflect volume overload. It drives discontinuation in a clinically meaningful minority of patients and is the main tolerability complaint with long-term amlodipine use.

Less Common but Serious Tolerability Issues

Lisinopril carries a risk of angioedema in approximately 0.1-0.7% of patients, with Black patients experiencing angioedema at 3-5 times the rate of non-Black patients [7]. Angioedema is a class-specific ACE inhibitor effect and can be life-threatening. This risk accumulates with time on therapy and does not decrease after the first year. Amlodipine does not carry an angioedema risk.

Amlodipine may cause reflex tachycardia and flushing, particularly at initiation, but these effects tend to attenuate over the first 4-8 weeks of therapy.

Racial and Ethnic Differences in Long-Term Response

The 2017 ACC/AHA Hypertension Guidelines state that for Black patients with hypertension but without heart failure or chronic kidney disease, thiazide-type diuretics and calcium channel blockers (such as amlodipine) are preferred as initial therapy [8]. Renin-angiotensin system agents including lisinopril are less effective as monotherapy in Black patients because of lower average renin levels in this population.

In ALLHAT, the stroke risk with lisinopril versus chlorthalidone was most pronounced in Black participants (RR 1.40 for stroke) [1]. This is a durable finding that has been replicated in multiple observational datasets and influences the clinical decision for a significant portion of the hypertensive population in the United States.

For patients of East Asian ancestry, lisinopril's high cough rate (30-40%) often makes amlodipine the more durable long-term choice simply by virtue of adherence rates.

Metabolic Effects Over Time

Long-term antihypertensive therapy can affect glucose metabolism, lipid panels, and kidney function over years.

Glucose and Diabetes Risk

ACE inhibitors including lisinopril are consistently associated with a reduced incidence of new-onset type 2 diabetes, with a meta-analysis of 12 trials showing a 14% reduction in new diabetes diagnoses compared with placebo or active control [9]. Amlodipine is metabolically neutral on glucose. For patients with pre-diabetes or strong family history of type 2 diabetes, lisinopril carries an additional metabolic reason to be preferred over the long term.

Renal Protection in Diabetic Nephropathy

Lisinopril and other ACE inhibitors reduce proteinuria and slow the progression of diabetic nephropathy independently of blood pressure reduction [10]. In patients with type 1 or type 2 diabetes plus microalbuminuria, the ACC/AHA guidelines recommend an ACE inhibitor or ARB as first-line, not a CCB. For this subpopulation, lisinopril's long-term durability of renal benefit clearly exceeds what amlodipine provides.

Lipid and Uric Acid Effects

Neither lisinopril nor amlodipine has a clinically meaningful effect on LDL cholesterol or triglycerides over long-term follow-up. Lisinopril does not raise uric acid; thiazide diuretics do, which is one reason ACE inhibitors are preferred over diuretics in patients with gout. Amlodipine is also uric acid-neutral. Neither drug meaningfully alters long-term lipid profiles.

When to Switch From Lisinopril to Amlodipine

Switching from lisinopril to amlodipine is clinically appropriate in specific scenarios. The following framework covers the most common clinical decision points for a provider managing a patient already on lisinopril.

Scenario 1: ACE Inhibitor Cough That Impairs Quality of Life

If a patient has been on lisinopril for any duration and develops a persistent dry cough that does not resolve after 4 weeks, switching is warranted. The first-line alternative is typically an ARB (losartan 50 mg or valsartan 80 mg), because ARBs maintain the renin-angiotensin blockade without the bradykinin-driven cough. If the patient has a reason to avoid ARBs (cost, prior trial without benefit), switching to amlodipine 5 mg daily is reasonable. Blood pressure should be reassessed at 2-4 weeks after the switch.

Scenario 2: Inadequate Systolic Control Despite Dose Optimization

If a patient is at maximum lisinopril dose (40 mg daily) and systolic blood pressure remains above 130 mmHg on two consecutive readings 4 weeks apart, adding amlodipine rather than switching is the preferred strategy. The combination of an ACE inhibitor plus a CCB is one of the most studied and effective antihypertensive combinations. ASCOT-BPLA's perindopril plus amlodipine arm demonstrates that this combination produces superior long-term cardiovascular outcomes compared to beta-blocker plus diuretic [2].

Scenario 3: New Diagnosis of Heart Failure With Reduced Ejection Fraction

If a patient on amlodipine develops HFrEF (ejection fraction <40%), lisinopril (or another ACE inhibitor or ARB/ARNI) should be added and titrated to target dose. Amlodipine can generally be continued for blood pressure control in HFrEF, as the PRAISE-1 trial found no harm signal for amlodipine in non-ischemic HFrEF [11], but ACE inhibitor therapy is mandatory and takes priority for mortality benefit.

Scenario 4: Black or East Asian Patients With Inadequate Response

For Black patients not at blood pressure goal on lisinopril monotherapy, adding or switching to amlodipine is guideline-concordant and supported by ALLHAT's racial subgroup data [1]. The combination of amlodipine plus an ARB or ACE inhibitor is effective in this population and avoids the differential stroke risk observed with ACE inhibitor monotherapy in ALLHAT.

Combination Therapy: Amlodipine Plus Lisinopril as a Long-Term Strategy

A substantial fraction of hypertensive patients do not achieve goal blood pressure on monotherapy. The JNC-8 report and the 2017 ACC/AHA Hypertension Guidelines both endorse combination therapy when a single agent does not bring systolic blood pressure below 130 mmHg (for high-risk patients) or 140 mmHg (for most others) [8].

The combination of amlodipine plus an ACE inhibitor or ARB has strong evidence behind it. In ACCOMPLISH (N=11,506, mean follow-up 2.9 years), benazepril plus amlodipine reduced the primary cardiovascular event rate by 19.6% compared with benazepril plus hydrochlorothiazide (hazard ratio 0.80, 95% CI 0.72-0.90, P<0.001) [12]. While benazepril is not lisinopril, the two drugs share the same class and mechanism. Combining amlodipine with lisinopril produces additive blood pressure reductions of approximately 10-15 mmHg systolic over monotherapy and is available as a fixed-dose combination tablet (amlodipine/benazepril, Lotrel; amlodipine/lisinopril is available as a generic combination in some markets).

The ACC/AHA 2017 guidelines state: "For adults with stage 2 hypertension and average blood pressure more than 20/10 mmHg above their target, initiation of 2 first-line drugs from different classes is recommended, either as separate agents or in a fixed-dose combination" [8]. Amlodipine and lisinopril together satisfy this recommendation and their complementary mechanisms (renin-angiotensin blockade plus vasodilation through calcium channel blockade) produce synergistic blood pressure reduction without pharmacokinetic interactions.

Adherence Data and Real-World Durability

Clinical trial durability is best-case durability. Real-world adherence data for antihypertensives suggest that 50% of patients have discontinued their initial antihypertensive agent within 12 months of starting therapy, regardless of drug class [13]. The practical durability of lisinopril versus amlodipine therefore also depends on which drug patients are more likely to keep taking.

In a retrospective cohort of over 200,000 hypertensive patients drawn from the UK Clinical Practice Research Datalink, amlodipine and ACE inhibitors had similar 12-month persistence rates (approximately 55-60%), while the primary driver of ACE inhibitor discontinuation was cough and the primary driver of CCB discontinuation was peripheral edema [13]. Patients who experienced neither side effect showed essentially equivalent long-term persistence between the two drug classes.

For a given patient, the drug with fewer tolerability barriers will be the one they take consistently for years, and consistent use beats pharmacokinetic superiority every time.

Dosing Reference for Long-Term Management

| Drug | Starting Dose | Target Dose | Maximum Dose | Dose Adjustment in CKD (GFR <30) | |---|---|---|---|---| | Lisinopril | 5-10 mg daily | 20-40 mg daily | 40 mg daily | Start at 2.5-5 mg; titrate slowly | | Amlodipine | 5 mg daily | 5-10 mg daily | 10 mg daily | No dose adjustment needed |

Patients with GFR <30 mL/min/1.73 m² on lisinopril require careful monitoring of serum potassium and creatinine. Amlodipine requires no renal dose adjustment, which simplifies long-term management in patients with CKD who are not yet on ACE inhibitors for their renal-protective indication.